Database→GHRP-2

Tier 2-3GH SecretagogueBody CompositionAnti-agingPREMIUM

GHRP-2

GHRP-2 (Pralmorelin) -- Growth Hormone Releasing Peptide-2, GHS-R1a Agonist

Approved in Japan as prescription diagnostic agent (GHRP Kaken 100 / pralmorelin) for GH deficiency assessment in adults and children. Not FDA-approved for any indication. FDA Category 2 (cannot be compounded in USA as of 2026; expected to remain Category 2 after 2026 reclassification due to cortisol and prolactin elevation concerns). WADA Prohibited List S2.2: GH-Releasing Peptides -- prohibited at all times by name (pralmorelin).

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

GHRP-2 (pralmorelin) is a synthetic hexapeptide GHS-R1a agonist and the most potent traditional GH-releasing peptide. It is the only GH secretagogue with regulatory approval anywhere in the world -- approved in Japan since 2004 as a diagnostic agent for GH deficiency. Unlike the more selective ipamorelin, GHRP-2 also elevates cortisol and prolactin at therapeutic doses, a distinguishing pharmacological liability. A negative 48-week intranasal growth trial in 126 GH-deficient children found no benefit on height SD score.

🔒

Full Profile: Premium Members Only

The complete GHRP-2 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use